These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21985754)

  • 21. Missense mutation of the beta-cardiac myosin heavy-chain gene in hypertrophic cardiomyopathy.
    Arai S; Matsuoka R; Hirayama K; Sakurai H; Tamura M; Ozawa T; Kimura M; Imamura S; Furutani Y; Joh-o K
    Am J Med Genet; 1995 Sep; 58(3):267-76. PubMed ID: 8533830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypertrophic cardiomyopathy due to beta-myosin heavy chain mutation with extreme phenotypic variability within a family.
    Keller DI; Schwitter J; Valsangiacomo ER; Landolt P; Attenhofer Jost CH
    Int J Cardiol; 2009 May; 134(3):e87-93. PubMed ID: 18374998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3.
    Oliva-Sandoval MJ; Ruiz-Espejo F; Monserrat L; Hermida-Prieto M; Sabater M; García-Molina E; Ortiz M; Rodríguez-García MI; Núñez L; Gimeno JR; Castro-Beiras A; Valdés M
    Heart; 2010 Dec; 96(24):1980-4. PubMed ID: 21088121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of large gene deletions and duplications in MYBPC3 and TNNT2 in patients with hypertrophic cardiomyopathy.
    Bagnall RD; Yeates L; Semsarian C
    Int J Cardiol; 2010 Nov; 145(1):150-3. PubMed ID: 19666196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiac troponin I mutations in Australian families with hypertrophic cardiomyopathy: clinical, genetic and functional consequences.
    Doolan A; Tebo M; Ingles J; Nguyen L; Tsoutsman T; Lam L; Chiu C; Chung J; Weintraub RG; Semsarian C
    J Mol Cell Cardiol; 2005 Feb; 38(2):387-93. PubMed ID: 15698845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations in the cardiac myosin-binding protein C gene are the predominant cause of familial hypertrophic cardiomyopathy in eastern Finland.
    Jääskeläinen P; Kuusisto J; Miettinen R; Kärkkäinen P; Kärkkäinen S; Heikkinen S; Peltola P; Pihlajamäki J; Vauhkonen I; Laakso M
    J Mol Med (Berl); 2002 Jul; 80(7):412-22. PubMed ID: 12110947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A substitution mutation in the myosin binding protein C gene in ragdoll hypertrophic cardiomyopathy.
    Meurs KM; Norgard MM; Ederer MM; Hendrix KP; Kittleson MD
    Genomics; 2007 Aug; 90(2):261-4. PubMed ID: 17521870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy.
    Van Driest SL; Jaeger MA; Ommen SR; Will ML; Gersh BJ; Tajik AJ; Ackerman MJ
    J Am Coll Cardiol; 2004 Aug; 44(3):602-10. PubMed ID: 15358028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genotype-phenotype analysis in four families with mutations in beta-myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy.
    Tesson F; Richard P; Charron P; Mathieu B; Cruaud C; Carrier L; Dubourg O; Lautié N; Desnos M; Millaire A; Isnard R; Hagege AA; Bouhour JB; Bennaceur M; Hainque B; Guicheney P; Schwartz K; Komajda M
    Hum Mutat; 1998; 12(6):385-92. PubMed ID: 9829907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Missing pieces: myosin binding protein C truncations in familial hypertrophic cardiomyopathy.
    Frenkel PA; Schneider MD
    Circ Res; 1997 Mar; 80(3):435-6. PubMed ID: 9048665
    [No Abstract]   [Full Text] [Related]  

  • 31. Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy.
    Perkins MJ; Van Driest SL; Ellsworth EG; Will ML; Gersh BJ; Ommen SR; Ackerman MJ
    Eur Heart J; 2005 Nov; 26(22):2457-62. PubMed ID: 16087648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse clinical course and poor prognosis of hypertrophic cardiomyopathy due to mutations in FHL1.
    Gallego-Delgado M; Gonzalez-Lopez E; Garcia-Guereta L; Ortega-Molina M; Gonzalez-Vioque E; Cobo-Marcos M; Alonso-Pulpon L; Garcia-Pavia P
    Int J Cardiol; 2015 Jul; 191():194-7. PubMed ID: 25965631
    [No Abstract]   [Full Text] [Related]  

  • 33. Symptomatic distal myopathy with cardiomyopathy due to a MYH7 mutation.
    Overeem S; Schelhaas HJ; Blijham PJ; Grootscholten MI; ter Laak HJ; Timmermans J; van den Wijngaard A; Zwarts MJ
    Neuromuscul Disord; 2007 Jun; 17(6):490-3. PubMed ID: 17383184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A frame shift mutation, Arg346fs mutation, is identified in cardiac myosin-binding protein C gene in a Chinese family with hypertrophic cardiomyopathy].
    Xie WL; Liu WL; Hu DY; Cui W; Zhu TG; Li CL; Sun YH; Li L; Bian H
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):963-6. PubMed ID: 16061003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mortality risk of untreated myosin-binding protein C-related hypertrophic cardiomyopathy: insight into the natural history.
    Nannenberg EA; Michels M; Christiaans I; Majoor-Krakauer D; Hoedemaekers YM; van Tintelen JP; Lombardi MP; ten Cate FJ; Schinkel AF; Tijssen JG; van Langen IM; Wilde AA; Sijbrands EJ
    J Am Coll Cardiol; 2011 Nov; 58(23):2406-14. PubMed ID: 22115648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma metalloproteinase levels and left ventricular remodeling in hypertrophic cardiomyopathy in patients with an identical mutation.
    Kitaoka H; Kubo T; Okawa M; Takenaka N; Baba Y; Yamasaki N; Matsumura Y; Furuno T; Doi YL
    J Cardiol; 2011 Nov; 58(3):261-5. PubMed ID: 21890325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical features of hypertrophic cardiomyopathy caused by an Arg278Cys missense mutation in the cardiac troponin T gene.
    Theopistou A; Anastasakis A; Miliou A; Rigopoulos A; Toutouzas P; Stefanadis C
    Am J Cardiol; 2004 Jul; 94(2):246-9. PubMed ID: 15246915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The G263X MYBPC3 mutation is a common and low-penetrant mutation for hypertrophic cardiomyopathy in the region of Asturias (Northern Spain).
    Reguero JR; Gómez J; Martín M; Flórez JP; Morís C; Iglesias S; Alonso B; Alvarez V; Coto E
    Int J Cardiol; 2013 Oct; 168(4):4555-6. PubMed ID: 23870641
    [No Abstract]   [Full Text] [Related]  

  • 39. Prevalence of the MYBPC3-A31P mutation in a large European feline population and association with hypertrophic cardiomyopathy in the Maine Coon breed.
    Mary J; Chetboul V; Sampedrano CC; Abitbol M; Gouni V; Trehiou-Sechi E; Tissier R; Queney G; Pouchelon JL; Thomas A
    J Vet Cardiol; 2010 Dec; 12(3):155-61. PubMed ID: 21051304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies.
    Meder B; Haas J; Keller A; Heid C; Just S; Borries A; Boisguerin V; Scharfenberger-Schmeer M; Stähler P; Beier M; Weichenhan D; Strom TM; Pfeufer A; Korn B; Katus HA; Rottbauer W
    Circ Cardiovasc Genet; 2011 Apr; 4(2):110-22. PubMed ID: 21252143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.